Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.

Hepato-gastroenterology - 1 May 2014

Kasuya Hideki, Kodera Yasuhiro, Nakao Akimasa, Yamamura Kazuo, Gewen Tan, Zhiwen Wu, Hotta Yoshihiro, Yamada Suguru, Fujii Tsutomu, Fukuda Saori, Tsurumaru Naoko, Kuwahara Toshie, Kikumori Toyone, Koide Yusuke, Fujimoto Yasushi, Nakashima Tsutomu, Hirooka Yoshiki, Shiku Hiroshi, Tanaka Maki, Takesako Kazuto, Kondo Touru, Aleksic Branko, Kawashima Hiroki, Goto Hidemi, Nishiyama Yukihiro

Abstract excerpt

Oncolytic virus therapy is a promising new therapeutic method, one of an eagerly anticipated class of biological therapies against cancer. There are many different classes of oncolytic virus. One of these, herpes oncolytic virus, is strongly oncolytic and has a large DNA genome as 150k bp. HF10 is a spontaneous mutant of herpes simplex virus -1 (HSV-1) that replicates within tumors and destroys cancers without...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus 1, Human

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Japan

Share to Neoplasm Staging

Share to Neoplasms

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Treatment Outcome

Share to Virus Replication

Source

Open in PubMed

Identifiers

PMID: 26176043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.PMID 26176043Read ↗

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.Semantic proximity Read ↗

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.Semantic proximity Read ↗

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].Semantic proximity Read ↗

Viral oncolysis by herpes simplex virus and other viruses.Semantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.Semantic proximity Read ↗

[Progess on research of herpes simplex virus type 1 mutants for cancer therapy].Semantic proximity Read ↗

Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic VirusesSemantic proximity Read ↗

Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Semantic proximity Read ↗

Enhancement of Oncolytic Activity of oHSV Expressing IL-12 and Anti PD-1 Antibody by Concurrent Administration of Exosomes Carrying CTLA-4 miRNASemantic proximity Read ↗

Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.